title: Transient receptor potential vanilloid type 1 channel may modulate opioid reward.
abstract: Transient receptor potential vanilloid type 1 (TRPV1), a nonselective cation channel, is a well-known pain-related receptor. TRPV1 involvement in morphine-induced antinociception, tolerance, and withdrawal symptoms has been previously reported. Emerging evidence indicates that TRPV1 may be related to both the cellular and behavioral effects of addictive drugs. In the present study, we investigated the role of TRPV1 in morphine reward using the conditioned place preference (CPP) paradigm in mice. Repeated morphine treatments upregulated TRPV1 expression in the dorsal striatum (DSt). Treatment with a TRPV1 agonist potentiated morphine reward, and pretreatment with TRPV1 antagonists attenuated these effects. Microinjection of a selective TRPV1 antagonist into the DSt significantly inhibited morphine-CPP. In addition, treatment with a TRPV1 antagonist suppressed morphine-induced increases in μ-opioid receptor binding, adenylyl cyclase 1 (AC1), p38 mitogen-activated protein kinase (p38 MAPK), and nuclear factor kappa B (NF-κB) expression in the DSt. Administering a p38 inhibitor not only prevented morphine-CPP, but also prevented morphine-induced NF-κB and TRPV1 activation in the DSt. Furthermore, injecting an NF-κB inhibitor significantly blocked morphine-CPP. Our findings suggest that TRPV1 in the DSt contribute to morphine reward via AC1, p38 MAPK, and NF-κB. Brain TRPV1 may serve as a novel therapeutic target to treat morphine-addictive disorders.
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Thi-Lien
authors.initials: TL
authors.lastname: Nguyen
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Seung-Hwan
authors.initials: SH
authors.lastname: Kwon
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Sa-Ik
authors.initials: SI
authors.lastname: Hong
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Shi-Xun
authors.initials: SX
authors.lastname: Ma
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Yang-Hee
authors.initials: YH
authors.lastname: Jung
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Ji-Young
authors.initials: JY
authors.lastname: Hwang
authors.affiliation: Neurotoxicology Program, College of Pharmacy, Korea Institute of Drug Abuse, Kangwon National University, Chuncheon, Republic of Korea.
authors.forename: Hyoung-Chun
authors.initials: HC
authors.lastname: Kim
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Seok-Yong
authors.initials: SY
authors.lastname: Lee
authors.affiliation: Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
authors.forename: Choon-Gon
authors.initials: CG
authors.lastname: Jang
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008813:Mice, Inbred ICR; D009020:Morphine / Q000494:pharmacology*; D016328:NF-kappa B / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism; D012201:Reward; D013028:Space Perception / Q000187:drug effects / Q000502:physiology; D050916:TRPV Cation Channels / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D000701:Analgesics, Opioid; D016328:NF-kappa B; D017450:Receptors, Opioid, mu; D050916:TRPV Cation Channels; C493921:TRPV1 protein, mouse; D009020:Morphine; D048051:p38 Mitogen-Activated Protein Kinases; D000262:Adenylyl Cyclases; C106670:adenylyl cyclase 1
references.citation: Curr Pharm Des. 2008;14(1):42-54
references.pmid: 18220817
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2689-94
references.pmid: 16477006
references.citation: Brain Res. 1991 May 10;548(1-2):100-10
references.pmid: 1651140
references.citation: Neuron. 1998 Sep;21(3):531-43
references.pmid: 9768840
references.citation: Behav Brain Res. 2011 Jan 20;216(2):592-6
references.pmid: 20816896
references.citation: Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):162-8
references.pmid: 15857679
references.citation: Science. 1997 Oct 3;278(5335):58-63
references.pmid: 9311927
references.citation: Mol Pharmacol. 2006 Nov;70(5):1742-9
references.pmid: 16914643
references.citation: Addict Biol. 2005 Mar;10(1):81-9
references.pmid: 15849022
references.citation: Brain Res Mol Brain Res. 2005 Jan 5;133(1):58-70
references.pmid: 15661365
references.citation: Behav Neurosci. 2004 Aug;118(4):740-50
references.pmid: 15301601
references.citation: Br J Anaesth. 2010 Nov;105(5):668-74
references.pmid: 20719804
references.citation: J Neurophysiol. 2004 May;91(5):2259-72
references.pmid: 14736863
references.citation: J Neurosci. 2008 May 28;28(22):5836-45
references.pmid: 18509045
references.citation: J Neurosci. 2005 Sep 21;25(38):8665-70
references.pmid: 16177034
references.citation: Neuropharmacology. 2009 Mar;56(4):814-20
references.pmid: 19705551
references.citation: Synapse. 1997 May;26(1):46-54
references.pmid: 9097404
references.citation: J Biol Chem. 1996 Dec 27;271(52):33308-16
references.pmid: 8969190
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references.pmid: 19710631
references.citation: Proteomics. 2006 Mar;6(6):2003-8
references.pmid: 16447156
references.citation: J Cell Sci. 2010 Jun 15;123(Pt 12):2045-57
references.pmid: 20483957
references.citation: J Neurosci. 2007 Jan 24;27(4):832-9
references.pmid: 17251423
references.citation: Trends Neurosci. 2005 Jan;28(1):37-43
references.pmid: 15626495
references.citation: Int J Mol Med. 2006 Oct;18(4):775-84
references.pmid: 16964434
references.citation: Nat Neurosci. 2010 Dec;13(12):1519-25
references.pmid: 21076424
references.citation: Eur J Neurosci. 2007 Apr;25(7):2191-200
references.pmid: 17419755
references.citation: BMC Pharmacol. 2011 Jul 18;11:6
references.pmid: 21767384
references.citation: Mol Pain. 2006 Jul 16;2:22
references.pmid: 16842630
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):291-5
references.pmid: 14751425
references.citation: J Neurosci. 2011 Mar 30;31(13):5067-77
references.pmid: 21451044
references.citation: Neuroscience. 2006;139(4):1405-15
references.pmid: 16603318
references.citation: Addiction. 2009 Apr;104(4):518-32
references.pmid: 19335651
references.citation: Trends Neurosci. 2009 Apr;32(4):215-24
references.pmid: 19285736
references.citation: J Neurosci. 1997 Oct 15;17(20):7890-901
references.pmid: 9315909
references.citation: Behav Brain Res. 2011 Mar 17;218(1):184-9
references.pmid: 21130118
references.citation: Nat Neurosci. 2008 Feb;11(2):152-9
references.pmid: 18204441
references.citation: Brain Res. 2012 Mar 20;1444:45-54
references.pmid: 22325096
references.citation: J Neurosci. 2007 Aug 1;27(31):8161-5
references.pmid: 17670959
references.citation: Neurosci Lett. 2011 Apr 8;493(1-2):29-32
references.pmid: 21315801
references.citation: Psychopharmacology (Berl). 2009 Aug;205(2):217-25
references.pmid: 19387617